SCHEMBL492856

SCHEMBL492856

O=C(COC1CCN(S(=O)(=O)c2c(Cl)cc(Cl)cc2Cl)C1)NC1CCC(C(c2ccccc2)N2CCCC2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.40
MEN1 O00255 2/20 0.40
POLB P06746 2/20 0.40
KMT2A Q03164 2/20 0.40
GAA P10253 2/20 0.40
ALDH1A1 P00352 5/20 0.39
TDP1 Q9NUW8 1/20 0.39
LMNA P02545 3/20 0.37
RAB9A P51151 2/20 0.37
ACLY P53396 2/20 0.36
PKM P14618 2/20 0.36
CACNA2D1 P54289 1/20 0.36
CACNA1B Q00975 1/20 0.36
CACNB1 Q02641 1/20 0.36
CACNA1C Q13936 1/20 0.36
NPC1 O15118 1/20 0.35
ATM Q13315 1/20 0.35
TSHR P16473 1/20 0.35
CNR1 P21554 2/20 0.35
CNR2 P34972 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL492834 0.96 SMN1; SMN2 (0.42) SMN1; SMN2MEN1POLBKMT2AGAA
SCHEMBL492643 0.93 MEN1 (0.42) SMN1; SMN2MEN1POLBKMT2AGAA
SCHEMBL492866 0.93 CACNA2D1 (0.43) SMN1; SMN2MEN1POLBKMT2AGAA
SCHEMBL492683 0.90 MEN1 (0.41) SMN1; SMN2MEN1POLBKMT2AGAA
SCHEMBL493670 0.90 CACNA2D1 (0.42) SMN1; SMN2MEN1POLBKMT2AGAA
SCHEMBL492870 0.89 FAAH (0.38) MEN1KMT2AALDH1A1TDP1ACLY
SCHEMBL493490 0.87 ALDH1A1 (0.38) SMN1; SMN2MEN1POLBKMT2AGAA
SCHEMBL493757 0.87 KMT2A (0.39) SMN1; SMN2MEN1POLBKMT2AGAA
SCHEMBL493282 0.86 SMN1; SMN2 (0.40) SMN1; SMN2MEN1POLBKMT2AGAA
SCHEMBL494103 0.85 EPHX2 (0.40) SMN1; SMN2MEN1POLBKMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106055-B2 Substituted amide compounds GRUENENTHAL GMBH (DE) 2012-01-31 US claimed
EP-2139851-A2 SUBSTITUTED AMIDE DERIVATIVES Grünenthal GmbH (DE) 2010-01-06 EP claimed
US-20080306084-A1 Substituted Amide Compounds GRUENENTHAL GMBH (DE) 2008-12-11 US claimed
WO-2008131946-A2 SUBSTITUTED AMIDE DERIVATIVES Grünenthal GmbH (DE) 2008-11-06 WO claimed
US-8106055-B2 Substituted amide compounds GRUENENTHAL GMBH (DE) 2012-01-31 US disclosed
EP-2139851-A2 SUBSTITUTED AMIDE DERIVATIVES Grünenthal GmbH (DE) 2010-01-06 EP disclosed
US-20080306084-A1 Substituted Amide Compounds GRUENENTHAL GMBH (DE) 2008-12-11 US disclosed
WO-2008131946-A2 SUBSTITUTED AMIDE DERIVATIVES Grünenthal GmbH (DE) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306084-A1 Substituted Amide Compounds OPRK1, NAA50, ACMSD SMN1; SMN2 1729/4885MEN1 4132/4885POLB 2120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.